Home / Treatments / Tesamorelin / Telehealth
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Disclosure: we may earn a commission if you use certain links on this page. Compensation does not change our published methodology, scoring, or editorial conclusions.
Written by Kim Callender, NP, FNP-BC·Reviewed by Jonathan Snipes, MD·Published July 12, 2026·Last reviewed July 12, 2026·Prices verified July 12, 2026·Methodology v1.0

Tesamorelin telehealth cost: what providers charge and how to evaluate a quote

Direct answer

Tesamorelin is a GHRH analogue and — importantly — one of the few peptides in this category that is <b>genuinely FDA-approved</b>, though for a narrow indication: the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is marketed as Egrifta. Everything else it is sold for is off-label.

What telehealth providers charge

We have not verified a price for thisWe do not publish a price for this treatment, because we have not verified one. Telehealth and longevity clinics advertise widely varying figures for NAD+, sermorelin and tesamorelin, and we have not yet captured and dated those prices against provider sources under our pricing-verification methodology.

Publishing an unverified number would be worse than publishing none. When we have captured them, they will appear here with a source and a verification date, exactly like our GLP-1 pricing.

Normalise any quote before you compare it

Because we will not hand you a number we cannot stand behind, the useful thing we can give you is the method — the same one we apply to GLP-1 pricing, where we do hold verified figures.

How to normalise a telehealth quote
Ask for…Because…
The total monthly cost, every fee includedSplit billing — medication plus a membership — is the commonest way a price looks lower than it is
The ongoing price, not the first monthIntroductory rates are customer-acquisition pricing. You pay the ongoing rate eleven months of twelve
Whether the price rises with doseA programme cheapest at the starting dose can be the most expensive at maintenance
What happens if you cancel earlyOn a committed plan this is the question most likely to cost you money
Whether labs and shipping are included'All-inclusive' is used loosely. Test it against specifics
The annual totalMonthly figures are how this is marketed; annual totals are how it is lived
Before you commit to a long planA committed plan lowers the monthly figure and raises the risk. Before you sign one, ask what happens if you stop early — because a meaningful number of people do. Roughly one in five patients discontinues a GLP-1 within the first few months, most often because of gastrointestinal side effects. Others stop because insurance unexpectedly approves a brand product, or because they reach a goal weight, or because their circumstances change.

Providers differ enormously in what happens then. Some refund the unused portion. Some convert you to the month-to-month rate and bill the difference for months already taken. Some refund nothing. This is the single question people most often forget to ask, and it is the one most likely to cost them money.

Frequently asked questions

What does Tesamorelin cost through telehealth?

We have not verified a price and will not publish one we cannot substantiate. This page gives you the method to evaluate any quote you are given.

Is Tesamorelin FDA-approved?

Tesamorelin (Egrifta) is FDA-approved, for one specific indication: excess visceral abdominal fat in HIV-infected patients with lipodystrophy. This is the strongest regulatory position of any peptide on this site, and it deserves to be stated clearly.

It also deserv

Does Tesamorelin work?

The approval rests on real randomised trial data showing a meaningful reduction in visceral adipose tissue in the HIV-lipodystrophy population, with associated improvements in triglycerides. That evidence is good.

It is also specific. There is no comparable trial evide

Sources

  1. U.S. Food and Drug Administration — approved labels and compounding guidance for this molecule.
  2. PubMed / NIH — indexed human clinical literature.
  3. ClinicalTrials.gov — registered trials, where they exist.
  4. Our source hierarchy and pricing-verification methodology.

Spotted an error? Submit a correction.